Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760,000 shares of common stock of Intercept Pharmaceuticals, Inc. (which included 360,000 additional shares that the underwriters purchased pursuant to their option to purchase additional shares), and the representatives of the several underwriters in connection with a concurrent SEC-registered offering by Intercept of $230 million aggregate principal amount of 2.00% convertible senior notes due 2026 (which included $30 million principal amount of convertible notes that the underwriters purchased pursuant to their option to purchase additional convertible notes). Intercept’s common stock is listed on the Nasdaq Global Select Market under the symbol “ICPT.”
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
The Davis Polk corporate team included partner Michael Kaplan and associates Roohi Gupte and David D. Kim. The Davis Polk equity derivatives team included partner John M. Brandow, and associate Katharine O’Banion. Counsel Patrick E. Sigmon and associate Joseph Jarashow provided tax advice. Partner David R. Bauer and associate Hilary Smith provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.